Back to top

pharmaceuticals: Archive

Zacks Equity Research

AZN Gets FDA Nod for Fasenra Label Expansion in Rare Disease

The FDA okays AstraZeneca's Fasenra for treating adults with eosinophilic granulomatosis with polyangiitis. This is the second approved indication for the drug.

REGNNegative Net Change SNYNegative Net Change AZNNegative Net Change GSKPositive Net Change

Zacks Equity Research

Zoetis Stock Rises 15% in 3 Months: Time to Add to Your Portfolio?

ZTS' innovative pet care products, along with efforts to expand the business, are expected to fuel significant growth in the future.

ILMNNegative Net Change ZTSPositive Net Change KRYSNegative Net Change FULCNegative Net Change

Zacks Equity Research

Novartis Wins FDA Approval of Kisqali for Early Breast Cancer

The FDA approves NVS' Kisqali to reduce the risk of disease recurrence in patients with HR+/HER2- early breast cancer.

NVSPositive Net Change PFENegative Net Change LLYNegative Net Change

Kinjel Shah

Eli Lilly Stock Up 21% in 6 Months: Time to Add to Your Portfolio?

Investors can buy LLY stock based on its strong overall financial performance and robust drug pipeline.

BIIBNegative Net Change NVONegative Net Change LLYNegative Net Change

Zacks Equity Research

Ascendis Soars on Encouraging Data From Dwarfism Drug Study

ASND stock surges after data from a study shows that its investigational achondroplasia therapy achieved the primary study goal.

BMRNNegative Net Change ILMNNegative Net Change ASNDNegative Net Change BVSNegative Net Change

Zacks Equity Research

Novartis' Kisqali Lowers Risk of Breast Cancer Recurrence by 28%

NVS' breast cancer drug Kisqali reduces the risk of disease recurrence by 28.5% in a broad population of patients suffering from early breast cancer.

NVSPositive Net Change PFENegative Net Change LLYNegative Net Change BAYRYNegative Net Change

Zacks Equity Research

NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study

NCNA stock surges 151% on positive efficacy data from the mid-stage melanoma study of NUC-7738 in combination with Merck's Keytruda.

BMYPositive Net Change MRKNegative Net Change ILMNNegative Net Change NCNAPositive Net Change

Zacks Equity Research

Zentalis Stock Up as FDA Lifts Partial Hold on Cancer Drug Studies

ZNTL stock gains as the FDA lifts clinical hold on studies of its lead candidate, azenosertib, which is being developed for different cancer indications.

GSKPositive Net Change ILMNNegative Net Change FULCNegative Net Change ZNTLNegative Net Change

Zacks Equity Research

Lilly Gets FDA Approval for Eczema Drug Ebglyss

The FDA approves Lilly's Ebglyss based on data from ADvocate 1, ADvocate 2 and ADhere studies.

NVSPositive Net Change BIIBNegative Net Change PFENegative Net Change LLYNegative Net Change

Nalak Das

Buy 3 High Dividend-Paying Stocks With Attractive Short-Term Returns

Three large-cap stocks ??? AES, PFE and UNM ??? currently offer attractive short-term returns along with a high dividend rate.

PFENegative Net Change UNMPositive Net Change AESPositive Net Change

Zacks Equity Research

Incyte Announces Promising New Data on Oncology Candidate at ESMO

INCY's INCB123667 data show the candidate's potential as a differentiated treatment option for cancers with increased cyclin E1 activity, amplification and/or overexpression in cells predictive of CDK2 dependency.

INCYNegative Net Change SNDXNegative Net Change KRYSNegative Net Change FULCNegative Net Change

Zacks Equity Research

Regeneron, SNY Win FDA Approval for a Broader Dupixent Label

REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.

REGNNegative Net Change SNYNegative Net Change RHHBYPositive Net Change

Zacks Equity Research

Instil Bio Stock Skyrockets 641% in One Week: Here's Why

A rival posted encouraging data on a drug that outperformed Keytruda in certain NSCLC patients. TIL licenses a drug candidate that uses a similar mechanism.

MRKNegative Net Change SMMTNegative Net Change TILPositive Net Change BVSNegative Net Change

Zacks Equity Research

IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study

Immuneering stock soars 41% as lead drug combo regimen shows superior initial efficacy in the first-line treatment of pancreatic cancer in a mid-stage study.

ILMNNegative Net Change KRYSNegative Net Change FULCNegative Net Change IMRXNegative Net Change

Zacks Equity Research

MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts

As part of its strategic prioritization, Moderna aims to cut its R&D expenses by 20% over the next four years. It decides to end five pipeline programs to save costs.

SNYNegative Net Change GSKPositive Net Change MRKNegative Net Change MRNANegative Net Change

Kinjel Shah

TEVA Stock Rises 72.5% This Year: Time to Buy, Sell or Hold?

Teva's reasonable valuation, an improving pipeline and the prospect of growth in sales and profits are good enough reasons for those who own the stock to stay invested.

SNYNegative Net Change JNJNegative Net Change TEVAPositive Net Change ABBVPositive Net Change

Zacks Equity Research

Roche Gets FDA Approval for Subcutaneous Formulation of Tecentriq

The FDA approves subcutaneous formulation of RHHBY's leading immunotherapy drug, Tecentriq, under the brand name Tecentriq Hybreza.

NVSPositive Net Change RHHBYPositive Net Change LLYNegative Net Change

Zacks Equity Research

Gilead Stock Rises as HIV Prevention Injection Meets Study Goals

GILD reports the success of its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, in a second late-stage study for the prevention of HIV.

GSKPositive Net Change GILDPositive Net Change KRYSNegative Net Change FULCNegative Net Change

Kinjel Shah

Pharma Stock Roundup: FDA Approves J&J's Tremfya for Ulcerative Colitis & More

FDA approves J&J's Tremfya for ulcerative colitis. NVO's oral obesity pill, amycretin, shows faster weight loss than weekly injection, Wegovy.

REGNNegative Net Change SNYNegative Net Change JNJNegative Net Change NVONegative Net Change

Zacks Equity Research

Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study

AURA stock up as lead candidate shows tumor control and visual acuity preservation abilities in eye cancer patients over 12 months of treatment.

ILMNNegative Net Change KRYSNegative Net Change FULCNegative Net Change AURANegative Net Change

Kinjel Shah

NVO Oral Obesity Pill Tops Wegovy; LLY, VKTX, GPCR Stocks Rise

Stocks of LLY, VKTX and GPCR, which make oral pills for obesity, rose on Wednesday in response to Novo Nordisk's positive data.

NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change GPCRPositive Net Change

Zacks Equity Research

Biotech Stock Roundup: TERN, SMMT Stocks Surge on Study Data, GSK's Vaccine Study Fails & More

Terns Pharmaceuticals and Summit Therapeutics are in the spotlight following positive updates on key candidates.

GSKPositive Net Change SMMTNegative Net Change IMVTNegative Net Change RLAYNegative Net Change TERNNegative Net Change

Zacks Equity Research

Novo Nordisk Stock Rises as Oral Obesity Pill Outshines Wegovy

NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage study.

NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change GPCRPositive Net Change

Zacks Equity Research

FDA Grants Label Expansion to J&J's Tremfya in Ulcerative Colitis

With this latest approval, JNJ's Tremfya is approved for a total of three immunology indications.

JNJNegative Net Change LLYNegative Net Change ABBVPositive Net Change

Ahan Chakraborty

Boost Your Portfolio's Health With These 4 Large-Cap Drug Stocks

Here are four big drug/biotech stocks, LLY, RHHBY, NVS and PFE, which you should buy today for lucrative long-term returns.

NVSPositive Net Change RHHBYPositive Net Change PFENegative Net Change LLYNegative Net Change